Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
Clinical trial NCT05713838 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05713838
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-28
- Primary completion
- 2027-01-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.